摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-苯氧基-2-糠酸 | 60698-32-0

中文名称
5-苯氧基-2-糠酸
中文别名
5-苯氧-2-糠酸
英文名称
5-phenoxy-furan-2-carboxylic acid
英文别名
5-Phenoxy-furan-2-carbonsaeure;5-phenoxy-2-furoic acid;5-Phenoxy-pyromucinsaeure;5-phenoxyfuran-2-carboxylic acid
5-苯氧基-2-糠酸化学式
CAS
60698-32-0
化学式
C11H8O4
mdl
MFCD01925067
分子量
204.182
InChiKey
QQKXTFLRAZKJJO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    121-123

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    59.7
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2932190090

SDS

SDS:31b41f84dd068043f889a708bf1664d8
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Arylamidoalkyl-N-hydroxyurea compounds having lipoxygenase inhibitory
    申请人:Abbott Laboratories
    公开号:US05514702A1
    公开(公告)日:1996-05-07
    The present invention provides certain (substituted carbocyclic aryl)amidoalkyl- and (substituted heterocyclic aryl)amidoalkyl-N-Hydroxy urea compounds which inhibit lipoxygenase enzyme activity and are thus useful in the treatment of allergic and inflammatory disease states.
    这项发明提供了一些抑制脂氧合酶酶活性的(取代的碳环芳基)氨基烷基-和(取代的杂环芳基)氨基烷基-N-羟基脲化合物,因此在治疗过敏和炎症性疾病状态中具有用处。
  • EP2 RECEPTOR AGONISTS
    申请人:Oxford Alexander William
    公开号:US20100130556A1
    公开(公告)日:2010-05-27
    A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R 5 is an optionally substituted C 5-20 aryl or C 4-20 alkyl group; L′ is a single bond, —O— or —C(═O)—; A is selected from the group consisting of: formulae (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR 3 ; S and CR 3 ; NH and CR 3 ; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formulae (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formulae (A) (B) where R P6 is selected from fluoro and chloro; and R 2 is either: (i) —CO 2 H; (ii) —CONH 2 ; (iii) —CH 2 —OH; or (iv) tetrazol-5-yl.
    公式(III)的化合物:或其盐、溶剂合物和化学保护形式,其中:R5是可选择取代的C5-20芳基或C4-20烷基基团;L′是单键,—O—或—C(═O)—;A选自以下组:式(i)(ii)(iii),其中X和Y选自以下组:O和CR3;S和CR3;NH和CR3;NH和N;O和N;S和N;N和S;和N和O,其中虚线表示适当位置的双键,Q是N或CH;D从以下中选择:式(i)(ii)(iii)(iv)(v)(vii)(viii)(ix)B从以下组中选择:式(A)(B),其中RP6选自氟和氯;R2是:(i)—CO2H;(ii)—CONH2;(iii)—CH2—OH;或(iv)四唑-5-基。
  • EP2 receptor agonists
    申请人:Asterand UK Limited
    公开号:US08080567B2
    公开(公告)日:2011-12-20
    A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20alkyl group; L′ is a single bond, —O— or —C(═O)—; A is selected from the group consisting of: formula (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formula (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formula (A) (B) where RP6 is selected from fluoro and chloro; and R2 is either: (i) —CO2H; (ii) —CONH2; (iii) —CH2—OH; or (iv) tetrazol-5-yl.
    化合物的化学式(III):或其盐,溶剂合物和化学保护形式,其中:R5是可选取代的C5-20芳基或C4-20烷基;L'是单键,-O-或-C(=O)-;A选自以下组:公式(i),(ii),(iii),其中X和Y选自以下组:O和CR3;S和CR3;NH和CR3;NH和N;O和N;S和N;N和S;和N和O,其中虚线表示适当位置的双键,Q为N或CH;D选自:公式(i),(ii),(iii),(iv),(v),(vii),(viii),(ix);B选自以下组:公式(A),(B),其中RP6选自氟和氯;R2为:(i)-CO2H;(ii)-CONH2;(iii)-CH2-OH;或(iv)四唑-5-基。
  • Notes - Ultraviolet Spectra of 2-Substituted Furans and 5-Substituted Methyl Furoates
    作者:Donald Manly、E. Amstutz
    DOI:10.1021/jo01354a601
    日期:1957.3
  • OLEJNIK A. F.; NOVITSKIJ K. YU.; BRATTSEVA L. V.; GUSKOVA T. A.; PERSHIN +, XIM.-FARMATSEVT. ZH. <KNFZ-AN> 1976, 10, HO 5, 65-69
    作者:OLEJNIK A. F.、 NOVITSKIJ K. YU.、 BRATTSEVA L. V.、 GUSKOVA T. A.、 PERSHIN +
    DOI:——
    日期:——
查看更多